The delays, first revealed in Regeneron’s Q2 report, were chalked up to manufacturing issues at Novo Nordisk-owned plants.

Regeneron Pharmaceuticals announced FDA extended review timelines to Q4 2025 for two regulatory submissions related to Eylea ...

Before Novo arrived as its owner, issues at the Bloomington facility caused a two-month delay for Eylea HD’s FDA approval ...

Pharmaceuticals announced that the Food and Drug Administration has extended the target action dates to Q4 of 2025 for two Eylea ...

Regeneron Pharmaceuticals, Inc. REGN delivered better-than-expected fourth-quarter 2022 results even though Eylea sales declined. Dupixent maintained its stellar performance, with progress on ...

Regeneron Pharmaceuticals (NASDAQ: REGN) is scheduled to announce Q4 earnings results on Friday, February 3rd, before market open. The consensus EPS Estimate is $10.01 (-57.8% Y/Y) and the ...

Reports Q4 revenue $3.79B, consensus $3.75B. “Regeneron’s (REGN) financial and commercial strength allows for continued investment in our industry-leading R&D pipeline, while simultaneously ...

View more earnings on REGNSee more from BenzingaCHMP Backs Sanofi-Regeneron's Dupixent For Asthma Patients Aged 6 - 11 Years With Type 2 InflammationRegeneron, Sanofi Withdraw FDA Application For ...

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) moved higher by 2.7% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 27.07% year over ...

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) reported fourth-quarter adjusted profit per share of $12.56 compared to $23.42, prior year. On average, 21 analysts polled by Thomson Reuters ...